Renata PLC’s Thyrox receives European approval

Renata PLC has received approval for its Levothyroxine Sodium tablets under the EU Decentralised Procedure (DCP) in Ireland, Germany, Italy, Poland, Portugal and Malta, according to a press release from the company.

Levothyroxine is a widely prescribed synthetic thyroid hormone used to treat hypothyroidism and other thyroid-related disorders.

For a potent product like Levothyroxine, which is responsible for the critical maintenance of metabolic functioning in patients, small changes in dose or product quality can significantly affect clinical response.

The product, being manufactured at Renata’s EU GMP-approved potent product facility, combined with robust quality controls and an R&D-focused formulation, helps ensure consistent dosing and patient safety.

Renata is the manufacturer and marketer of Thyrox, the company's Levothyroxine product in Bangladesh, where it is the brand leader in thyroid therapy.

Renata PLC intends to support safe and reliable access to Levothyroxine in the newly approved EU markets, as it has continued to do in Bangladesh.

Approval across six EU member states reflects Renata’s commitment to meeting stringent European regulatory standards and qualifying time and again to deliver high-quality medicines to patients across the world.